OncLive.com· @OncLive · X·· 21 小时前评分70
正文 · 原文
💥 Survival was improved with durvalumab plus enfortumab vedotin in patients with MIBC according to new data from the phase 3 VOLGA trial
Full details ➡️: https://www.onclive.com/view/durvalumab-plus-enfortumab-vedotin-improves-survival-in-cisplatin-ineligible-mibc
#oncology #blcsm #ESMO26 @myESMO
164 浏览 · 0 赞 · 2 转发 · 0 回复
会议摘要
LBA2按 Presidential Symposium I 对上
Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgVOLGA
https://esmocongress.esmo.org来源：OncLive.com · x.com